Authored By: Sarah
05 Jul 2024

 Intrauterine Contraceptive Devices (IUD) Market Size to grow by USD 965.49 million between 2023-2027

According to a research report “ Intrauterine Contraceptive Devices (IUD) Market” by Type (Hormonal intrauterine device, Copper intrauterine device) End-user (Hospitals, Gynecology clinics, Others) Geography (North America, Europe, APAC, Rest of World (ROW))- Global Forecast to 2027 published by Technavio, the market size is estimated to grow by USD 965.49 million, at a CAGR of  3.98% during the forecast period. The global IUD market is poised for significant growth due to the increasing prevalence of unintended pregnancies, a major public health concern and socioeconomic burden. According to the World Health Organization (WHO), approximately half of pregnancies among adolescent girls in developing countries are unintended. IUDs, as a reliable and effective long-term contraceptive solution, can help mitigate this issue. However, it's important to note that while IUDs offer numerous benefits, they do carry a risk of failure and require proper insertion and maintenance.

Browse market data tables, figures, and in-depth TOC on “Intrauterine Contraceptive Devices (IUD) Market” by Type (Hormonal intrauterine device, Copper intrauterine device) End-user (Hospitals, Gynecology clinics, Others) Geography (North America, Europe, APAC, Rest of World (ROW)) Global Forecast to 2027. Download Free Sample


By Type, the Hormonal intrauterine device segment is projected to dominate the market size in 2024

The hospitals sector represents the largest market share in the global Intrauterine Contraceptive Devices (IUD) market in 2023. Hospitals, particularly multispecialty hospitals, are significant consumers of IUDs. These hospitals offer a range of services, including gynecological surgeries, family planning advice, and contraception method information. With more than 500 beds, multispecialty hospitals cater to extensive medical requirements, providing inpatient, outpatient, and day-care services. They can be privately or government-owned. Mid-sized hospitals, accommodating 200-300 beds, also contribute significantly to the global IUD market.

By End-user, Hospitals  segment is expected to hold the largest market size for the year 2024

In the contraceptive market, hormonal intrauterine devices (IUDs) represent a highly effective and advanced solution for women seeking long-term pregnancy prevention. These devices release the hormone progestin, which inhibits ovulation by thinning the uterine lining and thickening cervical mucus, thereby obstructing sperm from reaching the egg and preventing fertilization. Hormonal IUDs offer additional benefits, such as a reduced risk of pelvic inflammatory disease (PID) and tubal pregnancies. Furthermore, they can help manage symptoms associated with conditions like polycystic ovary syndrome (PCOS) and endometriosis. Compared to copper IUDs, hormonal IUDs boast a superior efficacy rate and fewer complications and risks.

North America is forecasted to hold the largest market size by region in 2024

The Intrauterine Contraceptive Devices (IUD) market represents a significant growth opportunity for pharmaceutical and medical device companies. IUDs, which are small, T-shaped devices inserted into the uterus to prevent pregnancy, offer numerous advantages, including long-term effectiveness, convenience, and reversibility. The global IUD market is expected to expand at a robust CAGR due to increasing awareness, favorable reimbursement policies, and rising disposable income in emerging economies. Key players in this market include Bayer AG, Merck KGaA, and Hologic, Inc.

The Intrauterine Contraceptive Devices (IUD) Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • AbbVie Inc.
  • Bayer AG
  • DKT International
  • Durbin PLC
  • EurimPharm Arzneimittel GmbH
  • Gima Spa
  • HLL Lifecare Ltd.
  • Krishco Medical Products Pvt. Ltd.
  • Laboratoire HRA Pharma SAS
  • Melbea Innovations Ltd.
  • Meril Life Sciences Pvt. Ltd.
  • Ocon Medical Ltd.
  • Pregna International Ltd
  • Prosan International BV
  • SMB Corp. of India
  • The Cooper Companies Inc.
  • Viatris Inc.

For insights on company offerings- Request a sample report!

Research Analysis Overview

The Intrauterine Contraceptive Devices (IUD) market has witnessed significant growth in recent years due to the high prevalence of unplanned pregnancies and the need for effective and long-term birth control solutions. IUDs, which include hormonal devices like Liletta and LevoCept, and copper T380A devices, work by preventing fertilization of the egg by sperm or by inhibiting implantation of the fertilized egg in the uterus. Hormonal IUDs, such as those produced by Allergan and PRA Health Sciences, release low doses of hormones like progesterone or levonorgestrel, which thin the uterine lining and thicken cervical mucus to prevent sperm from reaching the egg. Copper IUDs, like Mirena, use copper ions to prevent fertilization. Community healthcare clinics and hospitals have played a crucial role in increasing the accessibility of IUDs, especially among adolescents and women in low-income communities. However, affordability remains a challenge for some, with estimations suggesting that discontinuation of schooling and unplanned pregnancy are common reasons for IUD discontinuation. Current trends indicate a shift towards more affordable and accessible IUD options. White blood cells play a role in the body's immune response to the IUD, and studies published on Gates Open Research suggest that IUDs may also have protective effects against pelvic inflammatory disease and endometrial cancer. Abortion is not a side effect of IUD use, and IUDs are an effective form of family planning for those seeking long-term, reversible birth control.

Market Research Overview

The Intrauterine Contraceptive Devices (IUD) market has witnessed significant growth in recent years due to the increasing awareness of family planning and the need to prevent unintended pregnancies. However, there are still challenges such as pain and bleeding associated with the use of IUDs, which can hinder their adoption. Novel strategies, including the development of hormone-free IUDs like the copper intrauterine device, are being explored to address these issues. The intrauterine devices market is segmented into hormonal devices like Liletta and Mirena, and non-hormonal devices like the copper IUD. Hormonal IUDs release hormones like prostaglandins and progesterone, while non-hormonal IUDs use copper ions for contraception. Despite the benefits of IUDs, lack of awareness and affordability remain major barriers to their widespread adoption, particularly in developing countries. Unsafe abortion due to unintended pregnancies is a significant issue, especially among adolescents. Healthcare infrastructure plays a crucial role in the adoption of IUDs. Ambulatory surgical centers, clinics, and hospitals are key players in the supplier-buyer network. Profit-oriented business decisions and unfavorable regulatory scenarios can also impact the market dynamics. Current trends suggest an increase in the prevalence of unplanned pregnancies, particularly among adolescents, due to premature sexual activity and discontinuation of schooling. Favorable regulatory scenarios and increasing awareness through initiatives like those by PRA Health Sciences, Allergan, and Gates Open Research, can help address these challenges and drive growth in the intrauterine devices market. In summary, the intrauterine devices market is poised for growth, but challenges such as pain, bleeding, lack of awareness, and affordability need to be addressed to increase adoption and reduce unintended pregnancies and unsafe abortions.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Read News Read Less
Interested in this report?
Get your sample now!